Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement
- PMID: 36830963
- PMCID: PMC9953577
- DOI: 10.3390/biomedicines11020425
Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement
Abstract
Background: Diagnosis of multiple sclerosis (MS) is established on criteria according to clinical and radiological manifestation. Cerebrospinal fluid (CSF) analysis is an important part of differential diagnosis of MS and other inflammatory processes in the central nervous system (CNS).
Methods: In total, 242 CSF samples were collected from patients undergoing differential MS diagnosis because of the presence of T2-hyperintensive lesions on brain MRI. The non-MS patients were subdivided into systemic inflammatory diseases with CNS involvement (SID) or cerebrovascular diseases (CVD) or other non-inflammatory diseases (NID). All samples were analyzed for the presence of oligoclonal bands and ELISA was performed for detection of: INF gamma, IL-6, neurofilaments light chain (NF-L), GFAP, CHI3L1, CXCL13, and osteopontin.
Results: The level of IL-6 (p = 0.024), osteopontin (p = 0.0002), and NF-L (p = 0.002) was significantly different among groups. IL-6 (p = 0.0350) and NF-L (p = 0.0015) level was significantly higher in SID compared to NID patients. A significantly higher level of osteopontin (p = 0.00026) and NF-L (p = 0.002) in MS compared to NID population was noted. ROC analysis found weak diagnostic power for osteopontin and NFL-L.
Conclusions: The classical and non-standard markers of inflammatory process and neurodegeneration do not allow for sufficient differentiation between MS and non-MS inflammatory CNS disorders. Weak diagnostic power observed for the osteopontin and NF-L needs to be further investigated.
Keywords: cerebrospinal fluid; differential diagnosis; interleukin 6; multiple sclerosis; neurofilaments light chain; oligoclonal bands; osteopontin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.PLoS One. 2020 May 21;15(5):e0233519. doi: 10.1371/journal.pone.0233519. eCollection 2020. PLoS One. 2020. PMID: 32437412 Free PMC article.
-
Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study.J Neuroinflammation. 2019 Mar 11;16(1):59. doi: 10.1186/s12974-019-1440-5. J Neuroinflammation. 2019. PMID: 30857557 Free PMC article.
-
Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis.PLoS One. 2013 Oct 8;8(10):e77163. doi: 10.1371/journal.pone.0077163. eCollection 2013. PLoS One. 2013. PMID: 24116216 Free PMC article.
-
Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update.Medicina (Kaunas). 2019 Jun 4;55(6):245. doi: 10.3390/medicina55060245. Medicina (Kaunas). 2019. PMID: 31167509 Free PMC article. Review.
-
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383. Int J Mol Sci. 2022. PMID: 35328802 Free PMC article. Review.
Cited by
-
No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules. 2025 Jan 6;15(1):68. doi: 10.3390/biom15010068. Biomolecules. 2025. PMID: 39858462 Free PMC article.
-
Differences in Brain Atrophy Pattern between People with Multiple Sclerosis and Systemic Diseases with Central Nervous System Involvement Based on Two-Dimensional Linear Measures.J Clin Med. 2024 Jan 6;13(2):333. doi: 10.3390/jcm13020333. J Clin Med. 2024. PMID: 38256467 Free PMC article.
-
Neurofilament Expression as a Biomarker of Post-COVID-19 Sudden Sensorineural Hearing Loss.Diseases. 2023 Jun 29;11(3):92. doi: 10.3390/diseases11030092. Diseases. 2023. PMID: 37489444 Free PMC article.
-
Recent advances in the diagnosis and management of neuropsychiatric lupus.Nat Rev Rheumatol. 2024 Nov;20(11):712-728. doi: 10.1038/s41584-024-01163-z. Epub 2024 Oct 2. Nat Rev Rheumatol. 2024. PMID: 39358609 Review.
-
Fluid Biomarkers in Demyelinating Spectrum Disorders: Past, Present, and Prospects.Int J Mol Sci. 2025 May 7;26(9):4455. doi: 10.3390/ijms26094455. Int J Mol Sci. 2025. PMID: 40362691 Free PMC article. Review.
References
-
- Wattjes M.P., Ciccarelli O., Reich D.S., Banwell B., de Stefano N., Enzinger C., Fazekas F., Filippi M., Frederiksen J., Gasperini C., et al. Magnetic Resonance Imaging in Multiple Sclerosis Study Group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–670. - PubMed
-
- Solomon A.J., Bourdette D.N., Cross A.H., Applebee A., Skidd P.M., Howard D.B., Spain R.I., Cameron M.H., Kim E., Mass M.K., et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016;87:1393–1399. doi: 10.1212/WNL.0000000000003152. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous